Cancer immunotherapies by design, and in development.

Our pipeline

Our efforts are targeting various cancer indications using our drug candidates either in monotherapy or in combination with additional drugs, as well as in intraportfolio combinations.



Phase 1

Phase 2

Phase 3


+ dostarlimab | 1L NSCLC PDL1high

Phase 2, planned

+ dostarlimab | HNSCC

Phase 2, active

+ dostarlimab + CD96 | Advanced Malignancies

Phase 1, active

+ dostarlimab + Inupadenant | Advanced Malignancies

Phase 1, planned

+ Inupadenant | Advanced Malignancies

Phase 2, active

Monotherapy/+ iberdomide | Relapsed Refractory Multiple Myeloma

Phase 2, active


Monotherapy | High Biomarker

Phase 2, active

+ pembrolizumab | PD-1 Resistant Melanoma

Phase 2, active

+ chemotherapy | 2L Chemo-naive NSCLC

Phase 2, active


IND Enabling Studies

Preclinical, active

Studies with dark backgrounds are active. Studies with light backgrounds are planned.

Child kissing older woman on cheek.

At iTeos we are pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics.

At iTeos, we believe that collaboration is critical to achieve our mission of developing breakthrough therapies. By building upon our talents and expertise, bringing out the best in each other, and working synergistically with the best scientists and technologies.

We bring our deep understanding of the tumor microenvironment and immunosuppressive pathways to design new products and improve the clinical benefit of oncology therapies.